<DOC>
	<DOCNO>NCT00032149</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness combine filgrastim combination chemotherapy treat patient HIV-related non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Filgrastim Treating Patients With HIV-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity mitoxantrone , cyclophosphamide , etoposide , vincristine , bleomycin , prednisolone , filgrastim ( G-CSF ) patient good-prognosis ( define study 1 adverse prognostic factor ) HIV-related non-Hodgkin 's lymphoma . - Determine effect regimen response rate , time disease progression , survival patient . OUTLINE : This multicenter study . Patients receive mitoxantrone IV , cyclophosphamide IV , etoposide IV day 1 ; vincristine IV bleomycin IV day 8 . Patients also receive prednisolone daily week 1-4 every day week 5-16 . Patients receive filgrastim ( G-CSF ) subcutaneously day 6-12 . Treatment repeat every 2 week 8 course ( 16 week ) absence disease progression unacceptable toxicity . Patients complete response ( CR ) partial response ( PR ) receive 4 course beyond CR PR . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 15-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated HIVrelated nonHodgkin 's lymphoma 1 following : Prior diagnosis acquire immune deficiency syndrome ( AIDS ) CD4 count &lt; 100,000/mm3 ECOG performance status &gt; 2 PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic : Not specify Chemotherapy : Not specify Endocrine : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
</DOC>